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In vain have you acquired knowledge, if you have not imparted it to
others.
Deuteronomy Rabbah c. 900
That big genomic datasets are necessary to power translational
studies would seem tautological save for the fact that sharing can be
the exception not the rule. Despite market incentives that encourage
data secrecy, there is growing agreement that broad data sharing is a
must if molecular medicine is to exist. Further, the expanding number
of global data repositories reﬂects the fact that disease risks are not
only inborn but involve widespread life style choices or exposures,
thus reinforcing our global interdependence. Thus, the promise of
improving health and prevention of disease will not be fulﬁlled, partic-
ularly on a global scale, unless data sharing is the norm. An increasing
number of initiatives are putting this sentiment into practice, some of
which are presented here.
If health care is a right, and medicine necessary, then public health,
global health, is a sociological and ethical as well as health problem.
The US Affordable Health Care Act supports this. Arguably, it
represents public afﬁrmation of a paradigm shift, away from actuarial
fairness, which bases one's obligations only on one's needs to a moral
commitment to the common good. A commitment to creating a health-
ier, andmore productive society, entails ensuring that the best available
clinical knowledge is accessible to all.
The notion of beneﬁt sharing was developed as a strategy to achieve
these goals and the framework has inﬂuenced new knowledge distribu-
tion strategies (Winkler et al., 2014; James et al., 2014).
The 2002 Budapest Open Access Initiative (http://www.
budapestopenaccessinitiative.org/) exempliﬁes a step in this direc-
tion. It established a moral imperative to advance knowledge through
collaboration and share it equally among better and worse resourced
entities. As such, the initiative represents a paradigm shift to a notion
of distributive justice based on the reality of interdependence and a
principal of solidarity. In doing so, it deﬁned the moral underpinnings
of scientiﬁc information sharing. However, the for-proﬁt nature of the
global health care industry incentivizes proprietary knowledge creation
and thus legitimized the secrecy of vast amounts of genomic and related
data, which remain siloed and locked to outsiders. Within these oppo-
site but parallel strategies – open and closed data systems – lies transla-
tional research.
This special issue calls attention to conﬂicting normsgoverning data/
knowledge sharing for the purpose of generating global dialogue about
how best to ensure that less resourced countries can contribute to im-
portant translational research and ultimately genomic beneﬁt sharing.http://dx.doi.org/10.1016/j.atg.2014.09.014
2212-0661/© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NCIt discusses current data/knowledge sharing practices, unmet needs in
advancing translational genomics and collectively raises the question
of what moral principles should guide data/knowledge sharing policy
decisions given that the health care industry is a free market enterprise.
We begin with Scully and Khoury's ‘What is Translational Genomics?
Going Beyond the Bedside to Improving Individual and Population
Health’. The authors demonstrate why translational genomic research
needs to go beyond the traditional “bench to bedside”model to include
improvements in healthcare and disease prevention. They discuss four
over arching phases of translational genomic research subsequent to
initial discovery and demonstrate why research is needed to determine
whether an innovative application is indicated for widespread routine
clinical use. Further, different types of research are needed; end-user
behavioral research, comparative effectiveness research, and adoption
research to assess whether dissemination and appropriate clinical inte-
gration have been achieved and whether or not disparities in access
have occurred. The promise of genomic medicine, they say, will not be
fulﬁlled until these phases of translational research are conducted.
The need to close scientiﬁc knowledge gap between better resourced
and less resourced areas of the world was recognized around the time
that the Budapest Open Access Initiative arose. In 2001, representatives
from the World Health Organization met with six of the largest interna-
tional scientiﬁc publishers and established HINARI Research in Health
to bridge this gap. In ‘HINARI: OpeningAccess in Biomedicine andHealth’,
Robertson discusses HINARI, its overall achievements and impact to date.
The program is funded through 2020.
The growing demand for transparency andopenness coupledwith the
increasing cost of drug development has prompted the pharmaceutical/
biotech industry to test out a new business model. Au's article, ‘The Shift
to an ‘Open’Model of Drug Development’ reviews the major factors driv-
ing pre-competitive collaborations. Although the parameters of the pre-
competitive space are not yet well deﬁned, the value of the approach is
that all participants gain the same information from a single source. For
industry, this translates as faster drug development and robust pipeline.
Collaborations between research scientists and citizens extend be-
yond the conﬁnes of clinical research. Citizen science embodies the
ethic of openness, making the process of conducting scientiﬁc research
available to the ‘masses’ for collaboration. Dr. Curtis's article, Online
Citizen Science Games: Opportunities for the Biological Sciences
takes us into the world of three successful biological citizens – or
crowdsourcing science – gaming formatted research projects; Foldit,
Phylo and EteRNA. Each harnesses the collective problem-solving
abilities of non-experts to accelerate scientiﬁc progress. Her research
found that a relatively smaller number of users are active players/
problem-solvers, likely due to the lengthy tutorials required and difﬁ-
culty of the games. Nonetheless, participants gain a high degree of-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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through crowdsourcing, with scientists often learning different ap-
proaches to problem solving. Thus, these types of collaboration have
been shown to bemutually beneﬁcialwhile instantiating a commitment
to society's common good.
Though the Open Source science movement is comparatively well
developed in the US and UK, little is known about open knowledge
projects in other parts of the world. Corbi and Thierry recently under-
took to close this gap by traveling the globe to identify and document
open knowledge projects in disparate parts of the world. ‘Open Steps:
a Journey to Discover and Document Open Knowledge Projects Around
the Globe’ describes a range of different types of open knowledge
projects, their challenges and community impact. It offers a glimpse
into how people in less resourced areas of the world are using newly
opened databases to solve important local problems. Among the pro-
jects discussed is DNAdigest, an initiative that provides a mechanism
for genomic data sharing among researchers situated in disparate
research settings as well as areas of the world. DNAdigest's mission is
to identify and remedy barriers to efﬁcient and ethical genomic data
sharing in the human genomic research.
In ‘The need to redeﬁne genomic data sharing: a focus on data acces-
sibility’ Shaik et al., present DNAdigest's qualitative study of clinical,
academic and industry researchers' experiencewith accessing and shar-
ing genomic data. Results reveal sharing barriers in discoverability and
accessibility and areas of researcher's frustrations. Solution strategies
are suggested.
One such solution strategy is discussed in the companion papers, ‘A
Collaborative Approach toDevelopMulti-OmicsData Analytics Platform
for Translational Research’, which is the ﬁrst of two papers, the second
will appear in the next issue. Addressing the well known pharmaceuti-
cal R & D need to analyze integrated datasets, such as clinical patient
data with high dimensional omics data, the authors describe a collabo-
ration between GeneData's Analytic platform and the tranSMART
knowledge management platform, which enables sharing, integration,
standardization and analysis of heterogeneous data. The paper demon-
strates the feasibility of linking academic, non-proﬁt and corporate re-
search communities for collaborations facilitated by tranSMART's
open-source platform. Schmacher et al., describe how the integration
of these platforms achieves data integration and facilitates big data an-
alytics, thus solving a formidable obstacle to translational research.
While a growing number of countries around the world are
conducting large-scale human genome sequencing and beneﬁting
from technological innovations that solve data sharing bottlenecks,
advance analysis and interpretation, overall goals will not be
reached, if a ﬂexible balance between protecting donor privacy rights
and permitting data access is not established. In Data Acquisition and
Data/Knowledge Sharing in Global Genomic Studies, Rotimi andMulder
discuss the importance of an approach that can overcome the chal-
lenges in less resourced areas of the globe, lest valuable data be avail-
able for use, beneﬁt only the developed world. They boldly call for
measures to improve the capacity (skills and infrastructure) of re-
searchers in the developing world to enable their ability contribute
equally. Failure to improve the skills and infrastructure for such
researchers, they contend, could easily result in their data becoming
publicly accessible too soon, due to funding requirements regarding
data sharing, thus barring their inability to publish ﬁrst, particularly in
light of difﬁculties in processing large volumes of data because of poor
internet connectivity. They call for publication embargoes that recog-
nize these limitations. Furthermore, data sharing and access policies
for primary and secondary use of data, they argue, must be fair in taking
into account constraints in the developing world and involve clear and
ethically robust consent process.
In ‘Genomic Knowledge Sharing’ Francis provides anupdated review
of legal and ethical issues related to genomic information sharing.
Achieving the common good, she claims, is served not only by genetic
information donor duties but genetic information recipient duties aswell. Individuals have a moral duty to share their genomic information
for the common good, provided that they know how their information
is to be shared and that they are protected against risks of disclosure.
Holders of individual data, she claims, also have important duties
which tend to be less recognized; namely to protect and ethically use
the individual data they are entrusted with. Reciprocal duties, she
claims, serve both justice and the common good.
Whether regulation is needed to ensure data sharing, as well as
ethical data sharing conduct is taken up by Chalmers et al., in ‘To
Share or Not to Share: Is the Question’. Their article examines whether
an international code of data sharing conduct can change attitudes
and practices towards more responsible and secure sharing of research
and clinical data. The question is discussed against the promulgation of
international principles governing ethical and legal conduct of genomic
research over the past twenty years. Legal and ethical pitfalls in interna-
tional genomic/clinical data sharing have begun to be addressed by the
Global Alliance for Genomic Health (GA4GH) which is developing a
Code of Conduct for International Data Sharing. Chalmers et al. argue
for institutional endorsement of the ethical principles laid out in this
GA4GH document. However, Chalmers et al., appropriately argue that
a rush to regulate should be tempered given the absence of data on spe-
ciﬁc legal barriers.
Interviews with Drs. Gholson Lyon and Jeantine Lunshof shed light
on the impact of data access data sharing practices on research progress.
Their respective views drive home just how powerful the impact of
existing requirements is on not only research but also, importantly, per-
sonal careers.
While many genomic databases are public and in theory freely
accessible to anybodywhomeets access requirements, there is a growth
of private companies sequencing organismsof interest. These databases,
or aspects of them, may be available for a cost which academicians are
normally unable to pay. Thus, a substantial amount of sequence infor-
mation is available only to big companies with deep pockets. Principles
of just and ethical data sharing run up against freemarket norms, raising
the question of whether the goals of translational research and promise
of precision medicine can be realized by all, globally. Angrist and Cook-
Deegan address this problem in ‘Distributing the Future: The Weak
Justiﬁcations for Keeping Human Genomic Databases Secret and the
Challenges and Opportunities in Reverse Engineering Them’. Drawing
on the negative market impact of Myriad's litigation and data secrecy
strategies, they discuss non-commercial efforts to recreate the secret
data, andwhy proprietary databases, or at least parts of them,will even-
tually, become open. Their vision of a redistributed future in which data
donation, sharing, and access not only support goals the common good
but also lead to the widespread beneﬁt sharing calls for not only a new
social contract but also a reengineered genetic testing and therapeutic
market. De-incentivizing data hoarding can surely beneﬁt research
and development in the less resourced parts of the world.
Regardless of how spectacularly genomics advances, if providers are
not competent to use newgenomic knowledge and tools in daily clinical
decision-making then the ﬁeld will have failed on its primary mission,
to improve detection, treatment and prevention through the practice
of molecular medicine. De Abrew, Dissanayake and Korf review major
challenges in educating providers across the globe. Scarcity in low and
middle-income countries hampers not only the affordability of technol-
ogies, but also slow adoption limits the ability to studywhether technol-
ogies improve health outcomes. Lacking convincing evidence of clinical
beneﬁt, they argue, compromises education efforts. They discuss the
pressing need to remedy cultural inequalities to develop minimum
standards of genetic competency within themedical community. Echo-
ing sentiments expressed by other authors of articles in this issue, they
discuss why infrastructure must be built and appropriately used if less
resourced clinical researcher can hope to conduct quality translational
research.
Electronic health records are one element of the needed infrastruc-
ture. As Fein points out in ‘Innovate of Die: Genomic data and Electronic
81EditorialHealth Records’, innovative solutions are needed to ensure that genomic
data resides within the EHR and thus serve clinical care. Ideally, the
developing world will adopt solutions that optimize the integration of
disparate data and avoid the mistakes and challenges that are all to
well known in the US.
Finally, Dr. Al-Mulla's commentary, ‘The Locked Genomes: A per-
spective from Arabia’, presents a range of data sharing challenges
faced in Kuwait. Their story is potent for it reveals both a passion to
advance genome knowledge and help patients and the grim reality
that without the ability to compare sequence variants, less resourced
countries will remain disadvantaged in an ability to participate in
global genomic research, as well as reap the beneﬁts that are hoped to
be shared globally.
The reasons to share data are increasingly evident and compelling.
Novel technological solutions to permit sharing across disparate do-
mains are increasingly available and principles governing appropriate
sharing will soon lead to practice standards. We ought not be fooled,
however, into believing that therefore open access, data sharing
and global beneﬁt sharing are a fait accompli. The ethos of open data/
knowledge sharing exists within a free market economy that prioritizes
considerations of ﬁnancial gain over justice for the less resourced. A
commitment to open access, global genomic data and knowledge shar-
ing reﬂects a call for a new social contract based on a principle of solidar-
ity and a duty to act for the common good. Such a new social contract
would likely entail asking companies to do things contrary to their
best ﬁnancial interests. Therefore, to ensure a paradigm shift, strategies
to ﬁnancially incentivize sharing are likely required. Equally important
are strategies to drive principles of beneﬁcence and distributive justice
for the less resourced. The time for principled global discussions thatensure global beneﬁt sharing is now. Pardon the pun, but a call for afﬁr-
mative action just may be the way to ensure fair play.
“Equality of opportunity is not enough. Unless we create an en-
vironment where everyone is guaranteed some minimum capa-
bilities through some guarantee of minimum income, education,
and healthcare, we cannot say that we have fair competition. When
some people have to run a 100 metre race with sandbags on their
legs, the fact that no one is allowed to have a head start does
not make the race fair. Equality of opportunity is absolutely neces-
sary but not sufﬁcient in building a genuinely fair and efﬁcient
society.”
[—Ha-Joon Chang, 23 Things They Don't Tell You About Capitalism]
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